CeQur

CeQur, founded in 2008 and headquartered in Switzerland, is a healthcare startup with a mission to simplify the lives of people with diabetes. The company focuses on developing and commercializing simple drug delivery devices that seamlessly integrate into daily life. CeQur has developed a 3-day bolus insulin delivery device, CeQur Simplicity, which has received FDA clearance and CE marking. This revolutionary device allows for discreet insulin administration with just the click of two buttons, offering a convenient and inject-free solution. With its recent Series C investment of $115.00M in April 13, 2021, CeQur has garnered support from notable investors including Schroders, VI Partners, Endeavour Vision, GMS Capital, Tandem Diabetes Care, Kingdon Capital Management, Credit Suisse Entrepreneur Capital, Federated Kaufmann Fund, and Ypsomed. The company is currently in a pilot launch stage with the CeQur Simplicity device, while further broad availability is anticipated. CeQur’s commitment to simplifying insulin delivery is underscored by its successful clinical studies, which have demonstrated the device's safety, effectiveness, and high patient satisfaction levels compared to daily injections. The company's efforts to bring innovative technology to patients and aid compliance with insulin therapy present potential for significant impact within the healthcare industry.